Literature DB >> 15755898

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Chihaya Imai1, Shotaro Iwamoto, Dario Campana.   

Abstract

Natural killer (NK) cells hold promise for improving the therapeutic potential of allogeneic hematopoietic transplantation, but their effectiveness is limited by inhibitory HLA types. We sought to overcome this intrinsic resistance by transducing CD56+CD3- NK cells with chimeric receptors directed against CD19, a molecule widely expressed by malignant B cells. An abundance of NK cells for transduction was secured by culturing peripheral blood mononuclear cells with K562 cells expressing the NK-stimulatory molecules 4-1BB ligand and interleukin 15, which yielded a median greater than 1000-fold expansion of CD56+CD3- cells at 3 weeks of culture, without T-lymphocyte expansion. Expression of anti-CD19 receptors linked to CD3zeta overcame NK resistance and markedly enhanced NK-cell-mediated killing of leukemic cells. This result was significantly improved by adding the 4-1BB costimulatory molecule to the chimeric anti-CD19-CD3zeta receptor; the cytotoxicity produced by NK cells expressing this construct uniformly exceeded that of NK cells whose signaling receptors lacked 4-1BB, even when natural cytotoxicity was apparent. Addition of 4-1BB was also associated with increased cell activation and production of interferon gamma and granulocyte-macrophage colony-stimulating factor. Our findings indicate that enforced expression of signaling receptors by NK cells might circumvent inhibitory signals, providing a novel means to enhance the effectiveness of allogeneic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755898      PMCID: PMC1895123          DOI: 10.1182/blood-2004-12-4797

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  69 in total

1.  Rapid and highly efficient gene transfer into natural killer cells by nucleofection.

Authors:  Hans-Ingo Trompeter; Sandra Weinhold; Corinna Thiel; Peter Wernet; Markus Uhrberg
Journal:  J Immunol Methods       Date:  2003-03-01       Impact factor: 2.303

2.  Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Proc R Soc Lond B Biol Sci       Date:  1954-12-15

3.  Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines.

Authors:  B Perussia; C Ramoni; I Anegon; M C Cuturi; J Faust; G Trinchieri
Journal:  Nat Immun Cell Growth Regul       Date:  1987

4.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors:  R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

Review 5.  Childhood acute lymphoblastic leukaemia--current status and future perspectives.

Authors:  C H Pui; D Campana; W E Evans
Journal:  Lancet Oncol       Date:  2001-10       Impact factor: 41.316

6.  Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.

Authors:  Thomas Schirrmann; Gabriele Pecher
Journal:  Cancer Gene Ther       Date:  2002-04       Impact factor: 5.987

Review 7.  Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect.

Authors:  Sherif S Farag; Todd A Fehniger; Loredana Ruggeri; Andrea Velardi; Michael A Caligiuri
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

8.  Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.

Authors:  Y K Tam; J A Martinson; K Doligosa; H-G Klingemann
Journal:  Cytotherapy       Date:  2003       Impact factor: 5.414

9.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

Authors:  H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

10.  Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.

Authors:  S Slavin; E Naparstek; A Nagler; A Ackerstein; S Samuel; J Kapelushnik; C Brautbar; R Or
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

View more
  250 in total

1.  Natural killer cell engineering for cellular therapy of cancer.

Authors:  D R Shook; D Campana
Journal:  Tissue Antigens       Date:  2011-12

Review 2.  Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.

Authors:  Martha Luevano; Alejandro Madrigal; Aurore Saudemont
Journal:  Cell Mol Immunol       Date:  2012-06-18       Impact factor: 11.530

3.  Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy.

Authors:  Tolga Sutlu; Sanna Nyström; Mari Gilljam; Birgitta Stellan; Steven E Applequist; Evren Alici
Journal:  Hum Gene Ther       Date:  2012-09-10       Impact factor: 5.695

4.  CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset.

Authors:  Sandra Lopez-Vergès; Jeffrey M Milush; Suchitra Pandey; Vanessa A York; Janice Arakawa-Hoyt; Hanspeter Pircher; Philip J Norris; Douglas F Nixon; Lewis L Lanier
Journal:  Blood       Date:  2010-08-23       Impact factor: 22.113

Review 5.  CAR-T Cell Therapy for Lymphoma.

Authors:  Carlos A Ramos; Helen E Heslop; Malcolm K Brenner
Journal:  Annu Rev Med       Date:  2015-08-26       Impact factor: 13.739

Review 6.  CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.

Authors:  G Elizabeth Pluhar; Christopher A Pennell; Michael R Olin
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

7.  Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.

Authors:  Wei Wang; Amy K Erbe; Kory A Alderson; Emily Phillips; Mikayla Gallenberger; Jacek Gan; Dario Campana; Jacquelyn A Hank; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2016-07-08       Impact factor: 6.968

Review 8.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

10.  Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.

Authors:  Jeffrey S Miller; Cliona M Rooney; Julie Curtsinger; Ron McElmurry; Valarie McCullar; Michael R Verneris; Natalia Lapteva; David McKenna; John E Wagner; Bruce R Blazar; Jakub Tolar
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-09       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.